Mexico Moves to Increase Tariffs on Asian Imports to Protect Domestic Industries 
SoftBank Eyes Switch Inc as It Pushes Deeper Into AI Data Center Expansion 
Asian Stocks Rally as Tech Rebounds, China Lags on Nvidia Competition Concerns 
S&P 500 Slides as AI Chip Stocks Tumble, Cooling Tech Rally 
Global Markets Slide as Tech Stocks Sink, Yields Rise, and AI Concerns Deepen 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Russia Stocks End Flat as Energy and Retail Shares Show Mixed Performance 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
BOJ Expected to Deliver December Rate Hike as Economists See Borrowing Costs Rising Through 2025 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
JD.com Pledges 22 Billion Yuan Housing Support for Couriers as China’s Instant Retail Competition Heats Up 
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Pfizer has acquired a stake in Valneva, a French biotech company, to jointly develop a vaccine for Lyme disease. The former entered into an Equity Subscription Agreement with Valneva and will begin collaboration for the development of a vaccine candidate.
According to Reuters, Pfizer, an American pharmaceutical and biotechnology corporation, will be investing $90.5 million euros or around $95.24 million for the acquisition of an 8.1% stake in Valneva. This is said to represent a price of €9.49 per share, and Pfizer is buying this via a reserved capital increase.
Once it receives the payment from Pfizer, it was reported that the French biotech firm would be using it to support its development contribution to the Lyme disease program, which is already in Phase 3. Pfizer and Valneva also updated the terms of their partnership as well as the license agreement for the VLA15 Lyme disease vaccine candidate. The companies first announced their collaboration in April 2020.
At any rate, Pfizer previously revealed that it is planning to start the Phase 3 study of VLA15 in the Q3 of this year. In the updated deal, Valneva will be funding 40% of the remaining shared costs in the development. Before the revision, the percentage was only 30%.
“Pfizer’s investment in Valneva highlights the quality of the work that we’ve done together over the past two years and is a strong recognition of Valneva’s vaccine expertise,” Valneva’s chief executive officer, Thomas Lingelbach, said in a press release. “Lyme disease is spreading and impacts the lives of millions of people so we are looking forward to further investigating our VLA15 candidate in Phase 3, which will take us a step closer to potentially help protect both adults and children from this devastating disease.”
Kathrin U. Jansen, Ph.D., Pfizer’s senior vice president and lead of vaccine research & development, further said, “As the geographic footprint of Lyme disease widens, the medical need for vaccination becomes even more imperative and we are excited to continue partnering with Valneva on the development of VLA15.”
Finally, Valneva and Pfizer’s equity investment is set to close on Wednesday, June 22.
